Lineage Cell Therapeutics reports fourth quarter and 2025 results Mar 5, 2026 04:01PM
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Mar 5, 2026 04:01PM
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 Feb 26, 2026 08:00AM
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience Jan 6, 2026 08:00AM
Lineage Cell Therapeutics outlines 2025 achievements and 2026 plans Jan 5, 2026 08:04AM
View Older Stories

Jan 5, 2026 08:00AM Lineage Cell Therapeutics Issues Letter to Stockholders
Nov 6, 2025 04:01PM Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Oct 30, 2025 08:00AM Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
Sep 8, 2025 08:00AM Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
Sep 2, 2025 08:00AM Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
Aug 26, 2025 08:03AM Lineage partners with William Demant Invest on hearing loss therapy
Aug 26, 2025 08:00AM Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
Aug 12, 2025 04:01PM Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 5, 2025 08:00AM Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
Aug 4, 2025 08:00AM Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
Jun 23, 2025 07:00AM OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
Jun 5, 2025 08:00AM Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
May 14, 2025 08:00AM Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
May 13, 2025 04:01PM Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025 08:00AM RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025
May 1, 2025 08:00AM Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025
Apr 22, 2025 08:00AM Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
Apr 21, 2025 08:00AM Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
Mar 10, 2025 04:05PM Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Mar 5, 2025 08:00AM Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025
Feb 11, 2025 08:00AM Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Feb 4, 2025 08:00AM Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Jan 27, 2025 04:05PM Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering
Jan 6, 2025 08:02AM Lineage Cell Therapeutics (LCTX) Issues Letter to Stockholders
Jan 6, 2025 08:00AM Lineage Cell Therapeutics Issues Letter to Stockholders
Nov 21, 2024 05:00PM Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Nov 20, 2024 08:01AM Lineage Cell Therapeutics (LCTX) Prices Up to $66M Share and Warrant Offering
Nov 20, 2024 08:00AM Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
Nov 14, 2024 04:01PM Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Nov 7, 2024 08:00AM Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Oct 14, 2024 08:00AM Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
Sep 25, 2024 08:00AM OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
Sep 18, 2024 08:00AM Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
Aug 13, 2024 08:00AM Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Aug 8, 2024 04:05PM Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Aug 1, 2024 08:00AM Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Jul 2, 2024 08:00AM Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
May 30, 2024 08:00AM Lineage to Present at 2024 BIO International Convention
May 21, 2024 08:00AM Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
May 9, 2024 04:01PM Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024 08:00AM OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
May 2, 2024 08:00AM Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
Apr 30, 2024 08:03AM Lineage Cell Therapeutics (LCTX) Receives Grant From California Institute for Regenerative Medicine
Apr 30, 2024 08:00AM Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
Apr 29, 2024 04:31PM Lineage Cell Therapeutics (LCTX) Announces Board Changes
Apr 29, 2024 04:30PM Lineage Announces Changes to Board of Directors
Apr 1, 2024 08:00AM Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
Mar 18, 2024 08:00AM Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
Mar 13, 2024 08:00AM RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Mar 11, 2024 08:00AM RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
View Older Stories